Subscribe

Your FREE subscription will give you access to articles, research reports, Biopharma CEO Confidence quarterly reports and much more!

Biopharmaceutical Practice Regulatory

Our Regulatory services are designed to help biopharmaceutical companies to solve complex regulatory challenges, as well as reduce risk and expedite the development process, by applying a premier level of expertise to every client engagement.

Service Lines Include:

5


Click the Tabs Below for Case Studies, White Papers, and Articles

Case Studies
Articles
Blog
  • Voice of Customer Study

    Situation: A joint venture between two European companies was looking to maximize the commercial potential of its automated plate reader

     

    Read this Case Study

  • Go-To-Market Strategy

    Situation: As a follow up to a pricing study, Kineticos was retained by a specialty laboratory to develop a comprehensive

     

    Read this Case Study

  • Oncology Commercial Assessment – Melanoma

    Situation: A clinical-stage oncology company with a potentially ground-breaking technology requested Kineticos to help determine which tumor type(s) had the

     

    Read this Case Study

  • Portfolio Prioritization – Oncology

    Situation: A publicly traded Oncology company with 3 technology platforms and limited resources was in need of narrowing their focus. 

     

    Read this Case Study

  • Commercial Assessment

    Situation: A mid-sized biotech company evaluating their Phase II Metabolic asset requested that Kineticos provide a commercial and financial assessment

     

    Read this Case Study

  • Business Development and Licensing

    Situation: A publicly traded pharmaceutical company seeking a strategic partner for their IND-ready asset was in need of support with

     

    Read this Case Study

  • Immuno-Oncology: In the Goldilocks Zone or Over-Invested?

    Written by Steve Buckanavage, Operating Executive, Kineticos It wasn’t that long ago that cancer was defined by the location in

     

    Read this Article

  • A Look Inside the Diagnostics Market

    The life science ecosystem is a complex organism being influenced by patients, providers, payers, and regulators in the precision medicine,

     

    Read this Article

  • Overall Confidence in the Biopharmaceutical Industry is Strong Heading into Q4 2018

    The life science industry is an evolving ecosystem and defined by the network of interactions between biopharmaceutical companies, services firms,

     

    Read this Article

  • A Primer on Oncology Diagnostics

    The trend towards personalized medicine in the oncology space has been rapidly gaining traction with the advent of genetic analysis

     

    Read this Article

  • Leveraging the Virtual Pharma Model

    Written by Mark Osterman, Senior Vice President, Kineticos My colleague, Dr. Soo Kim, recently wrote a piece about the evolution

     

    Read this Article

  • On the Importance of Primary Market Research

    Written by Myung Soo Kim, PhD, Research Analyst, Kineticos Pharmaceutical companies are frequently challenged with determining the optimal clinical development

     

    Read this Article

  • How Metrics Can Help Identify and Solve Operational Challenges

    Article Preview As the sophistication of operational practices across life sciences increases; unfortunately, so do the difficulty and complexity of

     

    Read this Blog Post

  • Growth by Acquisition in Life Sciences: Do You Have a Plan?

    Article Preview As the life sciences landscape continually changes, growth by acquisition has become increasingly common. Recent deals, such as

     

    Read this Blog Post

  • R&D Revolutionaries: Why the Actavis/Allergan Deal Takes a Stand for Biopharma’s True Roots in Innovation

    James Forte of Kineticos takes an in-depth look at the recent Actavis/Allergan deal including the role R&D innovation played in shaping the deal’s outcome. Let’s be candid. It’s been awhile since any biopharma company was able to claim R&D as a core competency with a straight face. Biopharma’s R&D efforts have long been challenged, and rightly so given its output, but the Actavis/Allergan deal shows that the right investment in R&D can revolutionize a business. Could efficient R&D be the new definition of innovation?

     

    Read this Blog Post

  • Driving Revenue and EBIDTA at CROs through Customer Loyalty

    Article Preview Determining customer satisfaction and loyalty is a difficult endeavor for most businesses. Traditional voice of customer surveys are

     

    Read this Blog Post

  • Merck KGaA and Bayer Choose Opposite Strategies

    Article Preview Europe’s two largest chemical and drug conglomerates are changing course in starkly opposite ways. As reported in recent

     

    Read this Blog Post

  • Next Generation Sequencing: Using Technology to Develop Mutually-Beneficial Partnerships

    Article Preview Arup Laboratories announced it will begin offering next-generation sequencing (NGS) based high resolution Human Leukocyte Antigen (HLA) genotyping

     

    Read this Blog Post


Contact Us Today to Discover How We Can Elevate Your Business Our Strategy Consulting Services Are Designed to Enhance Your Value

Contact Us Today
Top